Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
Thought Leadership
Latest Report
Biopharma and Medtech Half-Year Review 2021
Despite the continuing pandemic, the biopharma sector saw a return to relative stability during the first half of 2021. Remote operations are proving effective, deals are being made, and clinical research has resumed in many areas. Compared to the same period in 2020, the medtech industry has witnessed a reversal of fortunes. Those producing…
Report library
Evaluate Pharma World Preview 2021, Outlook to 2026
We provide top-level insights and analyses on all the key trends in the fourteenth edition of the Evaluate Pharma World Preview 2021, Outlook to 2026 report. Our most…
Evaluate Pharma World Preview 2021, Outlook to 2026 Infographic
This infographic showcases the key insights from the Evaluate Pharma World Preview, Outlook to 2026 report, at a time when the biopharma sector is under intense…
Evaluate Vantage Biopharma and Venture Capital: A Deep Dive
The sheer amount of private capital available to young drug developers the last few years is nothing new, however the Covid-19 pandemic has brought about an unprecedented…
Evaluate Vantage Report: US Approvals Under the Spotlight
On April 27-29, a three-day US advisory committee meeting convenes. Their objective is to scrutinise the accelerated approvals of certain anti-PD-(L)1 drugs whose…
Evaluate Vantage Pharma, Biotech & Medtech 2020 in Review
Despite the initial shock of the COVID-19 pandemic, 2020 was a standout year for biopharma. The top 600 biopharma companies added $487bn in market capitalisation, and…
